November 14, 2008 - Frequently Asked Questions and Answers – (FAQs)

From time to time, Investor Relations will provide FAQs on various topics of interest. The following is a recent FAQ.

Q What are the IMS prescription volumes for VYTORIN and ZETIA?

A U.S. Total Prescription Volume (000's)

	Jan. 2008	Feb. 2008	March 2008	April 2008	May 2008	June 2008
Cholesterol Management Market	20,519	19,042	19,788	19,645	19,910	19,403
Total Merck/Schering-Plough Franchise	3,226	2,790	2,820	2,507	2,479	2,351
VYTORIN	1,851	1,607	1,619	1,428	1,412	1,330
ZETIA	1,375	1,183	1,201	1,079	1,067	1,022

	July 2008	Aug. 2008	Sept. 2008	Oct. 2008
Cholesterol Management Market	20,292	19,666	19,923	20,640
Total Merck/Schering-Plough Franchise	2,376	2,233	2,171	2,186
VYTORIN	1,339	1,249	1,202	1,207
ZETIA	1,038	984	969	978

Source: IMS' ***National Prescription Audit Plus (NPA+)*** as of November 12, 2008 which includes routine refinements by IMS to previously published data.

DISCLOSURE NOTICE: The information in the frequently asked questions included in this FAQ, and in other written and oral statements about Schering-Plough and its business made by Schering-Plough or its officers from time to time, includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to prescription trends for VYTORIN and ZETIA.

Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factors could cause actual results to differ materially from Schering-Plough's forward-looking statements, including market forces (such as customer buying patterns); economic factors; product availability; patent and other intellectual property protection; current and future branded, generic or over-the-counter competition; the timing and outcomes of the regulatory process; the timing and outcomes of clinical trials; and prescriber, patient and media reaction to data obtained from post-marketing clinical trials, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Part II, Item 1A. "Risk Factors" in the third quarter 2008 10-Q, filed October 29, 2008.